Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorKelsey, Thomas W.
dc.contributor.authorMcConville, Lauren
dc.contributor.authorEdgar, Angela B.
dc.contributor.authorUngurianu, Alex I.
dc.contributor.authorMitchell, Rod T
dc.contributor.authorAnderson, Richard A.
dc.contributor.authorWallace, W. Hamish B.
dc.date.accessioned2017-07-24T14:30:08Z
dc.date.available2017-07-24T14:30:08Z
dc.date.issued2017-07-20
dc.identifier250376749
dc.identifier2806f9ce-45cb-4138-ab68-781a9a3ed29d
dc.identifier85026242700
dc.identifier000406634500066
dc.identifier.citationKelsey , T W , McConville , L , Edgar , A B , Ungurianu , A I , Mitchell , R T , Anderson , R A & Wallace , W H B 2017 , ' Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors ' , PLoS One , vol. 12 , no. 7 , e0181377 . https://doi.org/10.1371/journal.pone.0181377en
dc.identifier.issn1932-6203
dc.identifier.otherORCID: /0000-0002-8091-1458/work/35609713
dc.identifier.urihttps://hdl.handle.net/10023/11275
dc.descriptionFunding: RTM is supported by a Wellcome Trust Intermediate Clinical Fellowship (grant no: 098522), https://wellcome.ac.uk/what-we-do/directories/intermediate-clinical-fellowships-people-funded. TWK is supported by Engineering and Physical Sciences Research Council grant EP/P015638/1, http://gow.epsrc.ac.uk/NGBOViewGrant.aspx?GrantRef=EP/P015638/1.en
dc.description.abstractThe accuracy of Follicle Stimulating Hormone as a predictor of azoospermia in adult survivors of childhood cancer is unclear, with conflicting results in the published literature. A systematic review and post hoc analysis of combined data (n = 367) were performed on all published studies containing extractable data on both serum Follicle Stimulating Hormone concentration and semen concentration in survivors of childhood cancer. PubMed and Medline databases were searched up to March 2017 by two blind investigators. Articles were included if they contained both serum FSH concentration and semen concentration, used World Health Organisation certified methods for semen analysis, and the study participants were all childhood cancer survivors. There was no evidence for either publication bias or heterogeneity for the five studies. For the combined data (n = 367) the optimal Follicle Stimulating Hormone threshold was 10.4 IU/L with specificity 81% (95% CI 76%–86%) and sensitivity 83% (95% CI 76%–89%). The AUC was 0.89 (95%CI 0.86–0.93). A range of threshold FSH values for the diagnosis of azoospermia with their associated sensitivities and specificities were calculated. This study provides strong supporting evidence for the use of serum Follicle Stimulating Hormone as a surrogate biomarker for azoospermia in adult males who have been treated for childhood cancer.
dc.format.extent11
dc.format.extent419581
dc.language.isoeng
dc.relation.ispartofPLoS Oneen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectRJ Pediatricsen
dc.subjectDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRC0254en
dc.subject.lccRJen
dc.titleFollicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivorsen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Computer Scienceen
dc.contributor.institutionUniversity of St Andrews. Centre for Interdisciplinary Research in Computational Algebraen
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0181377
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record